Comparison of antihypertensive and metabolic effects of losartan and losartan in combination with hydrochlorathiazide - a randomized controlled trial

Abstract

L50H12.5C is an effective antihypertensive regimen in patients with moderate hypertension that is uncontrolled on 50 mg losartan monotherapy, and is the preferred treatment option in these patients compared with increasing the dose of losartan. The additional benefit of losartan on platelet inhibition was not evident in our population at these doses; however, there was evidence to suggest that the uricosuric effects of losartan might ameliorate the uric acid retention effects of therapy with hydrochlorothiazide.

Antiplatelet Effect of Losartan and Telmisartan in Patients With Ischemic Stroke

“…For the losartan group, these results agreed with previous in vivo studies showing significant differences in biomarkers of platelet activation. 13,17,22,23 Measurement of SPA represents an excellent method for detecting minute platelet aggregates as an index of platelet activation under conditions closer to the in vivo state than in the case of aggregation tests using inducers, 18 but significant differences were only observed in assay of CD62P levels in this study. CD62P might, thus, offer a more sensitive indicator of platelet activation than SPA.…”

“…21 The in vivo effect of losartan has been examined in patients with hypertension, but no significant difference was shown by platelet aggregation tests using agents such as ADP and ristocetin. 22,23 However, a significant difference was observed with respect to platelet aggregation stimulated by SFLRRN-NH2 (a thrombin receptor-activating peptide), and levels of platelet activation markers such as CD62P, CD63, and PAC-1. 13,17 Differing results among studies regarding the antiplatelet effects of losartan may, thus, result from differences in assay methods, whereas in vivo examina- tion of other ARBs have not yet been performed.…”

A New Fixed-Dose Combination for Added Blood Pressure Control: Telmisartan Plus Hydrochlorothiazide

“…37 A similar corrective effect on serum potassium levels has been reported with irbesartan, 38 and with ACE inhibitors including enalapril. 57 Amelioration of other HCTZ-induced adverse effects on metabolic parameters and electrolyte levels have been reported with losartan/HCTZ 45,58,59 and irbesartan/HCTZ. 38 …”

The Role of Losartan in Cost-effective Hypertension Control

“…However, at study end (12 weeks) only 6.9% (12/173) of patients receiving losartan-HCTZ reported cough compared with 16.5% (28/170) of those receiving enalapril-HCTZ (p = 0.005). Furthermore, losartan appeared to counteract the hyperuricemic effect of HCTZ seen in previous studies 15,40 .…”